306 related articles for article (PubMed ID: 28866799)
21. Nanoformulation: A Useful Therapeutic Strategy for Improving Neuroprotection and the Neurorestorative Potential in Experimental Models of Parkinson's Disease.
Lafuente JV; Requejo C; Carrasco A; Bengoetxea H
Int Rev Neurobiol; 2017; 137():99-122. PubMed ID: 29132545
[TBL] [Abstract][Full Text] [Related]
22. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter.
Xia CF; Boado RJ; Zhang Y; Chu C; Pardridge WM
J Gene Med; 2008 Mar; 10(3):306-15. PubMed ID: 18085726
[TBL] [Abstract][Full Text] [Related]
23. Long-term benefits of hematopoietic stem cell-based macrophage/microglia delivery of GDNF to the CNS in a mouse model of Parkinson's disease.
Ge G; Sivasubramanian BP; Geng BD; Zhao S; Zhou Q; Huang G; O'Connor JC; Clark RA; Li S
Gene Ther; 2024 May; 31(5-6):324-334. PubMed ID: 38627469
[TBL] [Abstract][Full Text] [Related]
24. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.
Requejo C; Ruiz-Ortega JA; Bengoetxea H; Garcia-Blanco A; Herrán E; Aristieta A; Igartua M; Ugedo L; Pedraz JL; Hernández RM; Lafuente JV
Mol Neurobiol; 2015 Oct; 52(2):846-58. PubMed ID: 26041662
[TBL] [Abstract][Full Text] [Related]
25. Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson's disease.
Pasquarelli N; Porazik C; Bayer H; Buck E; Schildknecht S; Weydt P; Witting A; Ferger B
Neurochem Int; 2017 Nov; 110():14-24. PubMed ID: 28826718
[TBL] [Abstract][Full Text] [Related]
26. Transcranial alternating current stimulation rescues motor deficits in a mouse model of Parkinson's disease via the production of glial cell line-derived neurotrophic factor.
Lee HJ; Jung DH; Jung YJ; Shin HK; Choi BT
Brain Stimul; 2022; 15(3):645-653. PubMed ID: 35429660
[TBL] [Abstract][Full Text] [Related]
27. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier.
Fu A; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2010 Sep; 1352():208-13. PubMed ID: 20599807
[TBL] [Abstract][Full Text] [Related]
28. inPentasomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice.
Rinaldi F; Seguella L; Gigli S; Hanieh PN; Del Favero E; Cantù L; Pesce M; Sarnelli G; Marianecci C; Esposito G; Carafa M
J Control Release; 2019 Jan; 294():17-26. PubMed ID: 30529726
[TBL] [Abstract][Full Text] [Related]
29. Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.
Zhao Y; Zhang Q; Xi J; Xiao B; Li Y; Ma C
Int J Clin Exp Pathol; 2015; 8(3):2354-64. PubMed ID: 26045742
[TBL] [Abstract][Full Text] [Related]
30. An injectable conductive Gelatin-PANI hydrogel system serves as a promising carrier to deliver BMSCs for Parkinson's disease treatment.
Xue J; Liu Y; Darabi MA; Tu G; Huang L; Ying L; Xiao B; Wu Y; Xing M; Zhang L; Zhang L
Mater Sci Eng C Mater Biol Appl; 2019 Jul; 100():584-597. PubMed ID: 30948095
[TBL] [Abstract][Full Text] [Related]
31. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
[TBL] [Abstract][Full Text] [Related]
32. Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in Parkinson's disease mouse model.
Lin CY; Hsieh HY; Chen CM; Wu SR; Tsai CH; Huang CY; Hua MY; Wei KC; Yeh CK; Liu HL
J Control Release; 2016 Aug; 235():72-81. PubMed ID: 27235980
[TBL] [Abstract][Full Text] [Related]
33. GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice.
Chen C; Li X; Ge G; Liu J; Biju KC; Laing SD; Qian Y; Ballard C; He Z; Masliah E; Clark RA; O'Connor JC; Li S
Sci Rep; 2018 Apr; 8(1):5460. PubMed ID: 29615705
[TBL] [Abstract][Full Text] [Related]
34. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
35. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice.
Kilic U; Kilic E; Dietz GP; Bähr M
Stroke; 2003 May; 34(5):1304-10. PubMed ID: 12677018
[TBL] [Abstract][Full Text] [Related]
36. The TAT protein transduction domain enhances the neuroprotective effect of glial-cell-line-derived neurotrophic factor after optic nerve transection.
Kilic U; Kilic E; Dietz GP; Bähr M
Neurodegener Dis; 2004; 1(1):44-9. PubMed ID: 16908973
[TBL] [Abstract][Full Text] [Related]
37. Estrogen Increases Striatal GDNF Immunoreactivity with no Effect on Striatal FGF-2 Immunoreactivity of MPTP-Treated Mice.
Tripanichkul W; Jaroensuppaperch EO
J Med Assoc Thai; 2015 Oct; 98 Suppl 9():S16-22. PubMed ID: 26817205
[TBL] [Abstract][Full Text] [Related]
38. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
[TBL] [Abstract][Full Text] [Related]
39. Erythropoietin and GDNF enhance ventral mesencephalic fiber outgrowth and capillary proliferation following neural transplantation in a rodent model of Parkinson's disease.
McLeod M; Hong M; Mukhida K; Sadi D; Ulalia R; Mendez I
Eur J Neurosci; 2006 Jul; 24(2):361-70. PubMed ID: 16903847
[TBL] [Abstract][Full Text] [Related]
40. Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
Sun X; Xiong Z; Zhang Y; Meng Y; Xu G; Xia Z; Li J; Zhang R; Ke Z; Xia Z; Hu Y
J Neurochem; 2012 Mar; 120(6):1072-83. PubMed ID: 22192054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
